More spending has lead to better health outcomes
That is according to a paper by Weaver et al. (2022). The authors use expenditure data from the Disease Expenditure Project and DALYs from the […]
Comparative Effectiveness
Why is investing in drugs to treat rare diseases an attractive investment for drug companies?
If you were a drug manufacturer, you naturally would want to focus your research on more common, highly prevalent diseases. If there are more patients […]
NICE’s new Severity Adjustment
In the United Kingdom, the National Institute for Health and Care Excellence (NICE) made an update to their health technology evaluations manual in January 2022. […]
What is wrong with QALYs?
A paper by Rand and Kesselheim (2021) in Health Affairs this month conducts a systematic literature review to answer this question. Based on 113 articles […]
Do most Medicare Part D drugs have CEA studies?
That is the question that a recent study by Tisdale et al. (2021) aim to answer. They first look at the top 250 Medicare Part […]
Technology assessment in rare diseases
What is a rare disease? The definition varies across countries, but according to the European Medicines Agency (EMA) rare diseases are those with a prevalence […]
What kind of HTA does the US need?
Should the US have a formal, centralized health technology assessment (HTA) organization? In the United Kingdom, the National Institute for Health and Care Excellence (NICE) […]
PCORI to incorporate cost but not cost-effectiveness in its new principles
Created by the Affordable Care Act (ACA) in 2010, the Patient-Centered Outcomes Research Institute (PCORI) has funded a wide variety of research comparing different treatments […]
The need for continuous cost-effectiveness analysis
At drug launch, treatments have some benefit and cost. However, drug prices may change over time. Additionally, treatment benefits may rise or fall depending on […]
